Home » Study: Neupro Transdermal System Shows Therapeutic Benefit in RLS
Study: Neupro Transdermal System Shows Therapeutic Benefit in RLS
UCB on Wednesday announced the results of a six-month, randomized, double-blind, placebo-controlled clinical study … showing that Neupro (rotigotine transdermal system, 2 and 3 mg/24 hours) provided sustained, clinically relevant improvements in symptoms of restless legs syndrome (RLS).
Forbes
Forbes
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May